Transforming growth factor-β3 is expressed in nondividing basal epithelial cells in normal human prostate and benign prostatic hyperplasia, and is no longer detectable in prostate carcinoma

Prostate

Volumn 31, Issue 2, 1997, Pages 103-109

  Djonov, Valentin ^a   Ball, Roland K ^a   Graf, Simon ^a   Mottaz, Alain E ^a,b   Arnold, Anna Marie ^a   Flanders, Kathy ^c   Studer, Urs E ^b   Merz, Vincent W ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

carcinoma; proliferation; prostate; TGF

Indexed keywords

MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BASAL CELL; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; STROMA CELL;

EID: 0030909041     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970501)31:2<103::AID-PROS5>3.0.CO;2-O     Document Type: Article

References (47)

1. Carter BS, Carter HB, Isaacs JT: Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate 16:187-197, 1990.
2. Carter HB, Coffey DS: The prostate: An increasing medical problem. Prostate 16:39-48, 1990.
3. Franks LM: Latent carcinoma of the prostate. J Pathol 68:603-616, 1954.
4. Akazaki K, Stemmermann SN: Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. Proc Natl Acad Sci USA 87:7762-7766, 1973.
5. Breslow N, Chan CW, Dhom G: Latent carcinoma of the prostate at autopsy in seven areas. Int J Cancer 20:680-688, 1977.
6. Mc Neal JE: Origin and development of carcinoma in the prostate. Cancer 23:24-34, 1969.
7. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger BA, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 319:525-532, 1988.
8. Land H, Parada LF, Weinberg RA: Tumorigenic conversion of primary embryo fibroblast requires at least 2 cooperating oncogenes. Nature 304:596-602, 1983.
9. Rassoulzadegan M, Cosle A, Carr A, Slaichenhaus N, Karman R, Cuzin F: The roles of individual polyomavirus early proteins in oncogenic transformation. Nature 360:713-718, 1982.
10. Fleming WH, Hamel A, McDonald R, Framesey E, Pettigrew MH, Johnston B, Dodd JG, Matusik RJ: Expression of the c-myc proto-oncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 46:345-354, 1990.
11. Carter BS, Epstein JI, Isaacs WS: Ras gene mutations in human prostate cancer. Cancer Res 50:6830-6832, 1990.
12. Peehl DM, Wehner N, Stamey TA: Activated Ki-ras oncogene in human prostatic adenocarcinoma. Prostate 10:281-289, 1987.
13. Bookstein R, Rio P, Mardreperla SA, Hong F, Allred C, Grizzle WE, Lee WH: Promoter deletion and loss of retinoblastoma gene expression in human prostate cancer. Proc Natl Acad Sci USA 87:7762-7766, 1990.
14. Merz VW, Miller GJ, Krebs T, Timme TL, Kadmon D, Park SH, Egawa S, Scardino PT, Thompson TC: Elevated transforming growth factor β1 and β3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: Evidence for a paracrine role during progression. Mol Endocrinol 5:503-513, 1991.
15. Mori H, Maki M, Oishi K, Joye M, Igarashi K, Yoshida O, Hatanaka M: Increasing expression of genes for basic fibroblast growth factor and transforming growth factor β2 in human benign prostatic hyperplasia. Prostate 16:71-80, 1990.
16. Steiner MS, Barrack ER: Transforming growth factor-β1 overproduction in prostate cancer: Effect on growth in vivo and in vitro. Mol Endocrinol 6:15-25, 1992.
17. Wilding G, Zugmeier G, Krabbe C, Flanders K, Gelmann E: Differential effects of transforming growth factor β on human prostate cancer cells in vitro. Mol Cell Endocrinol 65:7987, 1989.
18. Chomoczynski P, Sacchi N: Single-step method of RNA isolation by guanidinium-thiocyanate-phenol-chloro-form extraction. Anal Biochem 162:156-159, 1987.
19. Feinberg AP, Vogelstein B: A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132:6-13, 1983.
20. Derynck R, Jorrett JA, Chen EY, Goeddel DV: The murine transforming growth factor-β precursor. J Biol Chem 261:4377-4379, 1986.
21. Miller DA, Lee A, Pelton RW, Chen EY, Moses HL, Derynck R: Murine transforming growth factor-β2 cDNA sequence and expression in adult tissues and embryos. Mol Endocrinol 3:1108-1114, 1989.
22. Miller DA, Lee A, Matsui Y, Chen EY, Moses HL, Derynck R: Complementary DNA cloning of the murine transforming growth factor-β3 (TGF-β3) precursor and the comparative expression of TGF-β3 and TGF-β1 messenger RNA in murine embryos and adult tissues Mol Endocrinol 3:1926-1934, 1989.
23. Hanauer A, Mandel JL: The glyceraldhyde-3-phosphate-dehydrogenase gene family: Structure of a human cDNA and of an X chromosome linked pseudogene: Amazing complexity of the gene family in mouse. EMBO J 3:2627-2633, 1984.
24. Flanders KC, Thompson NL, Cissel DS, Van Oberghen-Schilling E, Baker C, Kass ME, Ellingsworth CR, Roberts A, Sporn, MB: Transforming growth factor β1: Histochemical localisation with antibodies to different epitopes. J Cell Biol 108:653-660, 1989.
25. Ten Dijke P, Thorikay M, Stewart A, Iwata KK: Recombinant expression and purification of transforming growth factor β3, a potent growth regulator. Ann NY Acad Sci 593:36-42, 1990.
26. Cordell JL, Falini B, Erber WN: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem 32:219-229, 1984.
27. Gerdes J, Schlüter C, Duchrow M, Wahlenberg C, Gerlach C: Immunobiochemical and molecular biologic characterization of the cell proliferation associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138:867-873, 1991.
28. Jacobs SC, Story MT, Sasse J, Lawson RK: Characterisation of growth factors derived from the rat ventral prostate. J Urol 139:1106-1110, 1988.
29. Hierowski MT, McDonald MW, Dunn L, Sullivan JW: The partial dependency of human prostatic growth factor on steroid hormones in stimulating thymidine incorporation into DNA. J Urol 139:909-912, 1987.
30. Story MT, Hopp KA, Meier DA, Begun FP, Lawson RK: Influence of transforming growth factor beta 1 and other growth factors on basic fibroblast growth factor level and proliferation of cultured human prostate-derived fibroblasts. Prostate 22:183-197, 1993.
31. Danielpour D, Kadomatsu K, Anzano MA, Smith JM, Sporn MB: Development and characterization of non-tumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res 54:3413-3421, 1994.
32. Knabbe C, Klein H, Zugmaier G, Voigt KD: Hormonal regulation of transforming growth factor beta-2 expression in human prostate cancer. J Steroid Biochem Mol Biol 47:137-142, 1993.
33. Glynne-Jones E, Harper ME, Goddard L, Eaton CL, Matthews PN, Griffiths K: Transforming growth factor beta 1 expression in benign and malignant prostatic tumors. Prostate 25:210-218, 1994.
34. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC: Association of transforming growth factor beta-1 with prostate cancer: An immunohistochemical study. Hum Pathol 24:4-9, 1993.
35. Rizzino A: Transforming growth factor β: Multiple effects in cell differentiation and extracellular matrices. Dev Biol 130:411-422, 1988.
36. Lyons RM, Moses HL: Transforming growth factors and the regulation of cell proliferation. Eur J Biochem 187:467-473, 1990.
37. Torre-Amione G, Beauchamp RD, Koepper H, Park BH, Schreiber H, Moses HL, Rowley DA: A highly immunogenic tumor transfected with murine transforming growth β1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87:1486-1490, 1990.
38. Welch DR, Fabra A, Nakajima M: Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 87:7678-6782, 1990.
39. Pelton RW, Hogan BLM, Miller DA, Moses HL: Differential expression of genes encoding TGF β1, β2, and β3 during murine palate formation. Dev Biol 141:456-460, 1990.
40. Pelton RW, Saxena B, Jones M, Moses HL, Gold LI: Immunohistochemical localization of TGF-β1, TGF-β2 and TGF-β3 in the mouse embryo: Expression patterns suggest multiple roles during embryonic development. J Cell Biol 115:1091-1105, 1991.
41. Timme TL, Truong LD, Merz VW, Krebs T, Kadmon D, Flanders KC, Park SH, Thompson TC: Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology 134:1039-1045, 1994.
42. Akhurst RJ, Fitzpatrick DR, Gatherer D, Lehnert SA, Millan FA: Transforming growth factor βs in mammalian embryogenesis. Prog Growth Factor Res 2:153-158, 1991.
43. Bascom CC, Wolfsohl JR, Coffey RJ, Madisen L, Webb NR, Purchio AF, Derynck R, Moses HL: Complex regulation of transforming growth factor β1, β2 and β3 expression in mouse fibroblast and keratinocytes by transforming growth factors β1 and β3. Mol Cell Biol 12:5508-5515, 1989.
44. Verhagen APM, Ramaekers FCS, Aalders TW, Schaafsma HE, Debruyne FMJ, Schalken JA: Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res 52:6182-6187, 1992.
45. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944, 1992.
46. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LW: c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 154:293-298, 1995.
47. Friedrich B, Gronberg H, Landstom M, Gullberg M, Bergh A: Differentiation-stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma. Prostate 27:102-109, 1995.